Figure 6 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Year: 2025
Type: other
Abstract: (A) Total CD8+ T cells, (B) intratumoral CD8+ T cells, (C) CD163+ TAMs, (D) CD66b+CD11b+ myeloid cells, (E) and FOXP3+ regulatory T cells by treatment arm in CANOPY-N. aCD163 is a marker for TAMs and was normalized by total detectable cells. bFOXP3 is a marker for regulatory T cells and was normalized by the abundance of CD3+ cells. CD66b expression is a marker for granulocytes including neutrophils, and CD11b is a marker for myeloid cells.
Authors: Benjamin J. Solomon, Daniel S.W. Tan, Gilberto de Castro, Manuel Cobo, Marina Chiara Garassino, Jun Zhang, Bruce E. Johnson, Jay M. Lee, Pilar Garrido, Andrew A. Butler, Marc R. Pelletier, Alexander Savchenko, Lexiang Ji, Jan C. Brase, Rafael Caparica, David Demanse, Jincheng Wu, Claudia Bossen, Tony Mok
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4410344384